Initially I was very disturbed with the PR regarding Top Line Results as I thought it was overly negative but upon reading it a number of times it really wasn't bad at all IMO. No matter what Leo said in the PR, the fact was that those holding the stock down swamped the early trading with massive sells assured that no amount of buying would have allowed it to recover IMO.

As to the upcoming PR giving further trial data on secondary matters and Compassionate Use results, I would like to see the PR written with the CU results given first (as I expect them to be the better of the two) and then follow with whatever data derives from the secondary data. Leo would emphasize the difference in dosage and dosings between the 2 sets of results to show that B is everything it was expected to be but needs to be given at a much higher dosage than was given in the trial and for severe patients possibly many more dosings.

All the above is predicated on the CU results being far better than the trial secondary endpoint results.